n(g),n(g')-dimethyl-l-arginine has been researched along with Chronic Kidney Diseases in 66 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide synthase with a key role in the pathophysiology of endothelial dysfunction, in the progression of atherosclerosis and in cardiovascular diseases." | 4.91 | Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches. ( Georgakis, MK; Latsios, G; Oikonomou, E; Papageorgiou, N; Papaioannou, S; Siasos, G; Tousoulis, D; Zaromitidou, M, 2015) |
| " Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)." | 3.83 | Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016) |
| "The purpose of the work was to study the impact of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme, dimethylarginine dimethylaminohydrolase (DDAH1), on atherosclerosis in subtotally nephrectomized (SNX) ApoE-deficient mice." | 3.80 | Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass. ( Arend, M; Cordasic, N; Hilgers, KF; Jacobi, J; Maas, R, 2014) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases." | 2.47 | The role of asymmetric and symmetric dimethylarginines in renal disease. ( Böger, RH; Schwedhelm, E, 2011) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| " Since disturbed NO bioavailability is a major pathway whereby high uric may cause renal damage, we tested the interaction between the major endogenous inhibitor of NO synthase, asymmetric-dimethylargine (ADMA), and the rs734553 polymorphism for CKD progression in the same cohort." | 1.42 | Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. ( Leonardis, D; Mallamaci, F; Pisano, A; Sanguedolce, MC; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2015) |
| "Symmetric dimethylarginine (SDMA) seems to be a good marker of multiorgan failure, especially renal failure." | 1.38 | Diagnostic value of plasma asymmetric and symmetric dimethylarginine levels in liver transplant recipients. ( Kokot, F; Kunsdorf-Wnuk, A; Wnuk, Z, 2012) |
| "Asymmetric dimethylarginine (ADMA) has been suggested as a possible marker of endothelial dysfunction, and interest in its use in clinical practice is increasing." | 1.36 | HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application. ( Artusi, C; Boffa, GM; Ivanova, M; Plebani, M; Zaninotto, M, 2010) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction." | 1.35 | Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. ( Beck, GJ; Collins, AJ; Greene, T; Kusek, JW; Menon, V; Sarnak, MJ; Terrin, N; Wang, X; Young, JM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (6.06) | 29.6817 |
| 2010's | 55 (83.33) | 24.3611 |
| 2020's | 7 (10.61) | 2.80 |
| Authors | Studies |
|---|---|
| Wołoszyk-Chojecka, P | 1 |
| Malgorzewicz, S | 1 |
| Chamienia, A | 1 |
| Puchalska-Reglińska, E | 1 |
| Dębska-Ślizień, A | 1 |
| Schrauben, SJ | 1 |
| Sapa, H | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Anderson, AH | 1 |
| Shlipak, MG | 1 |
| Hsu, CY | 1 |
| Shafi, T | 1 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| Chen, J | 3 |
| He, J | 3 |
| Ix, JH | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Kimmel, PL | 1 |
| Vasan, RS | 1 |
| Feldman, HI | 1 |
| Seegmiller, JC | 1 |
| Brunengraber, H | 1 |
| Hostetter, TH | 1 |
| Schelling, JR | 1 |
| Taguchi, K | 2 |
| Elias, BC | 1 |
| Brooks, CR | 1 |
| Ueda, S | 3 |
| Fukami, K | 2 |
| Ashokachakkaravarthy, K | 1 |
| Rajappa, M | 1 |
| Parameswaran, S | 1 |
| Satheesh, S | 1 |
| Priyadarshini, G | 1 |
| Mohan Raj, PS | 1 |
| Revathy, G | 1 |
| Priyadarssini, M | 1 |
| Corrêa, HL | 1 |
| Moura, SRG | 1 |
| Neves, RVP | 1 |
| Tzanno-Martins, C | 1 |
| Souza, MK | 1 |
| Haro, AS | 1 |
| Costa, F | 1 |
| Silva, JAB | 1 |
| Stone, W | 1 |
| Honorato, FS | 1 |
| Deus, LA | 1 |
| Prestes, J | 1 |
| Simões, HG | 1 |
| Vieira, EC | 1 |
| de Melo, GF | 1 |
| Moraes, MR | 1 |
| Rosa, TS | 1 |
| Wu, M | 1 |
| Yuan, M | 1 |
| Wang, Y | 1 |
| Tan, B | 1 |
| Huang, D | 1 |
| Wang, C | 1 |
| Zou, Y | 1 |
| Ye, C | 1 |
| Hamm, LL | 2 |
| Bundy, JD | 1 |
| Kumbala, DR | 1 |
| Bodana, S | 1 |
| Chandra, S | 1 |
| Chen, CS | 2 |
| Starcke, CC | 1 |
| Guo, Y | 1 |
| Schaefer, CM | 1 |
| Lustigova, E | 1 |
| Mahone, E | 1 |
| Vadalia, AM | 1 |
| Livingston, T | 1 |
| Obst, K | 1 |
| Hernandez, J | 1 |
| Bokhari, SR | 1 |
| Kleinpeter, M | 1 |
| Alper, AB | 1 |
| Lukitsch, I | 1 |
| He, H | 1 |
| Nieman, DC | 1 |
| Zhang, H | 1 |
| Xiang, S | 1 |
| Dai, Z | 1 |
| Fan, Y | 1 |
| Yokoro, M | 1 |
| Nakayama, Y | 1 |
| Yamagishi, SI | 1 |
| Ando, R | 1 |
| Sugiyama, M | 1 |
| Ito, S | 1 |
| Yano, J | 1 |
| Kaida, Y | 1 |
| Saigusa, D | 1 |
| Kimoto, M | 1 |
| Abe, T | 1 |
| Stojanovic, D | 1 |
| Cvetkovic, T | 1 |
| Stojanovic, M | 1 |
| Stefanovic, N | 1 |
| Velickovic-Radovanovic, R | 1 |
| Zivkovic, N | 1 |
| Eloot, S | 3 |
| Van Biesen, W | 2 |
| Roels, S | 1 |
| Delrue, W | 1 |
| Schepers, E | 2 |
| Dhondt, A | 2 |
| Vanholder, R | 3 |
| Glorieux, G | 3 |
| Emrich, IE | 1 |
| Zawada, AM | 1 |
| Martens-Lobenhoffer, J | 2 |
| Fliser, D | 2 |
| Wagenpfeil, S | 1 |
| Heine, GH | 1 |
| Bode-Böger, SM | 2 |
| Pang, P | 1 |
| Abbott, M | 1 |
| Abdi, M | 1 |
| Fucci, QA | 1 |
| Chauhan, N | 1 |
| Mistri, M | 1 |
| Proctor, B | 1 |
| Chin, M | 1 |
| Wang, B | 1 |
| Yin, W | 1 |
| Lu, TS | 1 |
| Halim, A | 1 |
| Lim, K | 1 |
| Handy, DE | 1 |
| Loscalzo, J | 1 |
| Siedlecki, AM | 1 |
| Wang, F | 1 |
| Xiong, R | 1 |
| Feng, S | 1 |
| Lu, X | 1 |
| Li, H | 1 |
| Wang, S | 1 |
| Triches, CB | 1 |
| Quinto, M | 1 |
| Mayer, S | 1 |
| Batista, M | 1 |
| Zanella, MT | 1 |
| Małyszko, J | 1 |
| Matuszkiewicz-Rowińska, J | 1 |
| Krzanowski, M | 1 |
| Krzanowska, K | 1 |
| Gajda, M | 1 |
| Dumnicka, P | 1 |
| Kopeć, G | 1 |
| Guzik, B | 1 |
| Woziwodzka, K | 1 |
| Dziewierz, A | 1 |
| Litwin, JA | 1 |
| Sułowicz, W | 1 |
| Liu, X | 1 |
| Xu, X | 1 |
| Shang, R | 1 |
| Chen, Y | 1 |
| Obayashi, K | 1 |
| Kurumatani, N | 1 |
| Saeki, K | 1 |
| Verkaik, M | 1 |
| Juni, RP | 1 |
| van Loon, EPM | 1 |
| van Poelgeest, EM | 1 |
| Kwekkeboom, RFJ | 1 |
| Gam, Z | 1 |
| Richards, WG | 1 |
| Ter Wee, PM | 1 |
| Hoenderop, JG | 1 |
| Eringa, EC | 1 |
| Vervloet, MG | 1 |
| Benito, S | 1 |
| Sánchez-Ortega, A | 1 |
| Unceta, N | 1 |
| Goicolea, MA | 1 |
| Barrio, RJ | 1 |
| Wieczorek-Surdacka, E | 1 |
| Hanff, E | 1 |
| Chyrchel, B | 1 |
| Kuźniewski, M | 1 |
| Surdacki, A | 1 |
| Tsikas, D | 1 |
| Oliva-Damaso, E | 1 |
| Oliva-Damaso, N | 1 |
| Rodriguez-Esparragon, F | 1 |
| Payan, J | 1 |
| Baamonde-Laborda, E | 1 |
| Gonzalez-Cabrera, F | 1 |
| Santana-Estupiñan, R | 1 |
| Rodriguez-Perez, JC | 1 |
| Gessner, A | 1 |
| Mieth, M | 1 |
| Auge, D | 1 |
| Chafai, A | 1 |
| Müller, F | 1 |
| Fromm, MF | 1 |
| Maas, R | 2 |
| Witasp, A | 1 |
| Rydén, M | 1 |
| Carrero, JJ | 2 |
| Qureshi, AR | 1 |
| Nordfors, L | 1 |
| Näslund, E | 1 |
| Hammarqvist, F | 1 |
| Arefin, S | 1 |
| Kublickiene, K | 1 |
| Stenvinkel, P | 1 |
| Pacurari, M | 1 |
| Xing, D | 1 |
| Hilgers, RH | 1 |
| Guo, YY | 1 |
| Yang, Z | 1 |
| Hage, FG | 1 |
| Yilmaz, MI | 3 |
| Sonmez, A | 2 |
| Saglam, M | 2 |
| Yaman, H | 1 |
| Unal, HU | 2 |
| Gok, M | 2 |
| Cetinkaya, H | 2 |
| Eyileten, T | 2 |
| Oguz, Y | 2 |
| Sari, S | 1 |
| Yildirim, AO | 1 |
| Vural, A | 2 |
| Blanco-Colio, LM | 1 |
| Sesti, G | 1 |
| Mannino, GC | 1 |
| De Lorenzo, C | 1 |
| Greco, A | 1 |
| Sciacqua, A | 1 |
| Marini, MA | 1 |
| Andreozzi, F | 1 |
| Perticone, F | 1 |
| Jacobi, J | 1 |
| Arend, M | 1 |
| Cordasic, N | 1 |
| Hilgers, KF | 1 |
| Eiselt, J | 1 |
| Rajdl, D | 1 |
| Racek, J | 1 |
| Vostrý, M | 1 |
| Rulcová, K | 1 |
| Wirth, J | 1 |
| Atzler, D | 1 |
| Schwedhelm, E | 2 |
| Nauck, M | 1 |
| Ittermann, T | 1 |
| Böger, RH | 2 |
| Friedrich, N | 1 |
| Claes, KJ | 1 |
| Bammens, B | 1 |
| Kuypers, DR | 1 |
| Meijers, B | 1 |
| Naesens, M | 1 |
| Sprangers, B | 1 |
| Vanrenterghem, Y | 1 |
| Lerut, E | 1 |
| de Loor, H | 1 |
| Evenepoel, P | 1 |
| Tripepi, G | 3 |
| Kollerits, B | 1 |
| Leonardis, D | 2 |
| Postorino, M | 1 |
| Mallamaci, F | 3 |
| Kronenberg, F | 1 |
| Zoccali, C | 3 |
| Testa, A | 1 |
| Spoto, B | 1 |
| Pisano, A | 1 |
| Sanguedolce, MC | 1 |
| Rroji, M | 1 |
| Neirynck, N | 1 |
| Vandennoortgate, N | 1 |
| Liabeuf, S | 1 |
| Massy, Z | 1 |
| Karaman, M | 1 |
| Haymana, C | 1 |
| Rizzo, M | 1 |
| Toth, PP | 1 |
| Chien, SJ | 2 |
| Lin, IC | 2 |
| Hsu, CN | 2 |
| Lo, MH | 2 |
| Tain, YL | 2 |
| Tousoulis, D | 1 |
| Georgakis, MK | 1 |
| Oikonomou, E | 1 |
| Papageorgiou, N | 1 |
| Zaromitidou, M | 1 |
| Latsios, G | 1 |
| Papaioannou, S | 1 |
| Siasos, G | 1 |
| Mohler, ER | 1 |
| Hudaihed, A | 1 |
| Arora, R | 1 |
| Liu, Y | 1 |
| Browne, G | 1 |
| Mills, KT | 1 |
| Kleinpeter, MA | 1 |
| Simon, EE | 1 |
| Rifai, N | 1 |
| Klag, MJ | 1 |
| Kielstein, H | 1 |
| Suntharalingam, M | 1 |
| Perthel, R | 1 |
| Song, R | 1 |
| Schneider, SM | 1 |
| Jäger, K | 1 |
| Kielstein, JT | 1 |
| Minakuchi, H | 1 |
| Wakino, S | 1 |
| Hosoya, K | 1 |
| Sueyasu, K | 1 |
| Hasegawa, K | 1 |
| Shinozuka, K | 1 |
| Yoshifuji, A | 1 |
| Futatsugi, K | 1 |
| Komatsu, M | 1 |
| Kanda, T | 1 |
| Tokuyama, H | 1 |
| Hayashi, K | 1 |
| Itoh, H | 1 |
| Dounousi, E | 1 |
| Torino, C | 1 |
| Pizzini, P | 1 |
| Cutrupi, S | 1 |
| Panuccio, V | 1 |
| D'Arrigo, G | 1 |
| Abd ElHafeez, S | 1 |
| Bartnicki, P | 1 |
| Kowalczyk, M | 1 |
| Franczyk-Skóra, B | 1 |
| Baj, Z | 1 |
| Rysz, J | 1 |
| Boelaert, J | 1 |
| Lynen, F | 1 |
| Asmarawati, TP | 1 |
| Thaha, M | 1 |
| Mardiana, N | 1 |
| Ardhany, AR | 1 |
| Tjempakasari, A | 1 |
| Santoso, D | 1 |
| Irwanadi, C | 1 |
| Parrish, AR | 1 |
| Zinellu, A | 1 |
| Sotgia, S | 1 |
| Mangoni, AA | 1 |
| Sotgiu, E | 1 |
| Ena, S | 1 |
| Satta, AE | 1 |
| Carru, C | 1 |
| Szymanek-Pasternak, A | 1 |
| Szymczak, A | 1 |
| Zalewska, M | 1 |
| Małyszczak, K | 1 |
| Knysz, B | 1 |
| Fuchs, D | 1 |
| Kurz, K | 1 |
| Gostner, JM | 1 |
| Abdelwhab, S | 1 |
| Lotfy, G | 1 |
| Abdelmaksoud, S | 1 |
| Young, JM | 1 |
| Terrin, N | 1 |
| Wang, X | 1 |
| Greene, T | 1 |
| Beck, GJ | 1 |
| Kusek, JW | 1 |
| Collins, AJ | 1 |
| Sarnak, MJ | 1 |
| Menon, V | 1 |
| Landim, MB | 1 |
| Casella Filho, A | 1 |
| Chagas, AC | 1 |
| Ivanova, M | 1 |
| Artusi, C | 1 |
| Boffa, GM | 1 |
| Zaninotto, M | 1 |
| Plebani, M | 1 |
| Shi, B | 1 |
| Ni, Z | 1 |
| Zhou, W | 1 |
| Yu, Z | 1 |
| Gu, L | 1 |
| Mou, S | 1 |
| Fang, W | 1 |
| Wang, Q | 1 |
| Cao, L | 1 |
| Yan, Y | 1 |
| Qian, J | 1 |
| Mihout, F | 1 |
| Shweke, N | 1 |
| Bigé, N | 1 |
| Jouanneau, C | 1 |
| Dussaule, JC | 1 |
| Ronco, P | 1 |
| Chatziantoniou, C | 1 |
| Boffa, JJ | 1 |
| Dupont, JJ | 1 |
| Farquhar, WB | 1 |
| Townsend, RR | 1 |
| Edwards, DG | 1 |
| Kajimoto, H | 1 |
| Kai, H | 1 |
| Aoki, H | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Aoki, Y | 1 |
| Okuda, S | 1 |
| Imaizumi, T | 1 |
| Bai, Y | 1 |
| Sun, L | 1 |
| Du, L | 1 |
| Zhang, T | 1 |
| Xin, W | 1 |
| Lan, X | 1 |
| Du, G | 1 |
| Dobrian, AD | 1 |
| Kimura, K | 1 |
| Wnuk, Z | 1 |
| Kokot, F | 1 |
| Kunsdorf-Wnuk, A | 1 |
| Marra, M | 1 |
| Marchegiani, F | 1 |
| Ceriello, A | 1 |
| Sirolla, C | 1 |
| Boemi, M | 1 |
| Franceschi, C | 1 |
| Spazzafumo, L | 1 |
| Testa, I | 1 |
| Bonfigli, AR | 1 |
| Cucchi, M | 1 |
| Testa, R | 1 |
| Tucker, PS | 1 |
| Dalbo, VJ | 1 |
| Han, T | 1 |
| Kingsley, MI | 1 |
| Nickolas, TL | 1 |
| Barasch, J | 1 |
| Devarajan, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial[NCT02552888] | Phase 2 | 70 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| The Prospective Cohort Study to Investigate the Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio To Predict Cardiovascular Outcomes in Chronic Kidney Disease.[NCT02113462] | 197 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | umol/mL (Mean) |
|---|---|
| Treatment | 0.03 |
| Placebo | 0.02 |
A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | log (ng/mL) (Mean) |
|---|---|
| Treatment | -0.02 |
| Placebo | -0.01 |
A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | log (pg/g) (Mean) |
|---|---|
| Treatment | -0.01 |
| Placebo | 0.23 |
Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Treatment | 0.1 |
| Placebo | 0.2 |
A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: baseline, 6 weeks, 12 weeks
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | -0.25 |
| Placebo | -0.13 |
A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | mg/mL (Mean) |
|---|---|
| Treatment | 0.05 |
| Placebo | -0.02 |
A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | log (pg/mL) (Mean) |
|---|---|
| Treatment | 0.07 |
| Placebo | -0.17 |
A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | ug/L (Mean) |
|---|---|
| Treatment | 166 |
| Placebo | 11.7 |
A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated. (NCT02552888)
Timeframe: Baseline,12 weeks
| Intervention | log (mg/dL) (Mean) |
|---|---|
| Treatment | -0.09 |
| Placebo | -0.01 |
A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| Treatment | -1.7 |
| Placebo | -0.3 |
A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Treatment | -10.9 |
| Placebo | 62.2 |
A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | umol/L (Mean) |
|---|---|
| Treatment | 15.4 |
| Placebo | -6.3 |
A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | micromol/L (Mean) |
|---|---|
| Treatment | -0.07 |
| Placebo | -0.11 |
Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | beat/minute (Mean) |
|---|---|
| Treatment | 0.6 |
| Placebo | -0.5 |
A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | log (mg/g) (Mean) |
|---|---|
| Treatment | 0.04 |
| Placebo | 0.02 |
FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | Percentage change (Mean) |
|---|---|
| Treatment | 1.1 |
| Placebos | 0.3 |
A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | Percentage change (Mean) |
|---|---|
| Treatment | -0.06 |
| Placebo | -0.05 |
Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Systolic blood pressure, mmHg | Diastolic blood pressure, mmHg | |
| Placebo | -0.7 | 0.1 |
| Treatment | -2.2 | -2.5 |
A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| ICAM, ng/mL | VCAM-1, ng/mL | E-Selecint, ng/mL | vWF, ng/mL | |
| Placebo | -4.0 | -10.8 | 1.06 | 2744 |
| Treatment | -16.1 | -22.2 | -0.32 | -683 |
A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-α (TNF-a), interleukin-17 (IL-17), interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline, 6 weeks, 12 weeks
| Intervention | pg/mL (Mean) | |||
|---|---|---|---|---|
| TNF-a, pg/mL | IL-17, pg/mL | IL-1 beta, pg/mL | MCP-1, pg/mL | |
| Placebo | -0.04 | 0.01 | -30.5 | 0.6 |
| Treatment | -0.04 | -0.72 | -17.1 | -6.0 |
A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model. (NCT02552888)
Timeframe: Baseline,12 weeks
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Total Cholesterol, mg/dL | LDL-cholesterol, mg/dL | HDL-cholesterol, mg/dL | |
| Placebo | 3.9 | 0.9 | 2.2 |
| Treatment | -1.6 | -1.9 | 0.9 |
13 reviews available for n(g),n(g')-dimethyl-l-arginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome.
Topics: Arginine; Cardio-Renal Syndrome; Glycation End Products, Advanced; Humans; Methylamines; Renal Insuf | 2019 |
Asymmetric dimethylarginine level as biomarkers of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis.
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Cause of Death; Humans; Mortality; Renal Insufficienc | 2021 |
Association of Circulating Levels of ADMA with Carotid Intima-Media Thickness in Patients with CKD: a Systematic Review and Meta-Analysis.
Topics: Arginine; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Humans; Renal In | 2018 |
Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Endothelium, Vascular; Heart Failure; Humans; Nitric Oxide Synth | 2018 |
Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.
Topics: Aging; Animals; Arginine; Cardiovascular Diseases; Endothelium, Vascular; Humans; Metabolic Networks | 2019 |
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.
Topics: Alzheimer Disease; Animals; Arginine; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hy | 2015 |
The cytoskeleton as a novel target for treatment of renal fibrosis.
Topics: Actins; Animals; Arginine; Cytoskeleton; Disease Progression; Epithelial Cells; Fibrosis; Humans; Ki | 2016 |
Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.
Topics: Animals; Arginine; Atherosclerosis; Biomarkers; Endothelium, Vascular; Humans; Nitric Oxide; Renal I | 2009 |
The role of asymmetric and symmetric dimethylarginines in renal disease.
Topics: Arginine; Humans; Kidney; Renal Insufficiency, Chronic; Risk Factors | 2011 |
Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: evidence from 6168 participants.
Topics: Adult; Aged; Arginine; Carotid Intima-Media Thickness; Epidemiologic Studies; Female; Humans; Kidney | 2013 |
[Methylarginies-induced endothelial dysfunction in chronic kidney disease].
Topics: Animals; Arginine; Cardiovascular Diseases; Disease Models, Animal; Endothelium, Vascular; Enzyme In | 2012 |
Clinical and research markers of oxidative stress in chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Advanced Oxidation Protein Products; Arginine; Biomarkers; Clini | 2013 |
Biomarkers in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Arginine; Biomarkers; Cystatin C; Cystatins; Fatty Acid-B | 2008 |
4 trials available for n(g),n(g')-dimethyl-l-arginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Resistance training improves sleep quality, redox balance and inflammatory profile in maintenance hemodialysis patients: a randomized controlled trial.
Topics: Aged; Arginine; Biomarkers; Endothelium; Humans; Inflammation; Male; Middle Aged; Muscle Strength; N | 2020 |
Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial.
Topics: Aged; Amine Oxidase (Copper-Containing); Antioxidants; Arginine; Biomarkers; Cell Adhesion Molecules | 2020 |
Homocysteine and Arginine-to-Asymmetric Dimethylarginine Ratio Associated With Blood Pressure Abnormalities in Children With Early Chronic Kidney Disease.
Topics: Adolescent; Arginine; Blood Pressure; Child; Cross-Sectional Studies; Female; Homocysteine; Humans; | 2015 |
Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease.
Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Comorbidity; | 2015 |
49 other studies available for n(g),n(g')-dimethyl-l-arginine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Prevalence of cardiovascular diseases in kidney transplant recipients and its relationship with asymmetric dimethylarginine, fibroblast growth factor-23 and multiple inflammatory markers.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fibroblast Growth Factor-23; Humans; Interl | 2022 |
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
Asymmetric dimethylarginine and angiopoietin-like protein-2 are independent predictors of cardiovascular risk in pre-dialysis non-diabetic chronic kidney disease patients.
Topics: Adolescent; Adult; Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Arginine; Biomarkers; Ca | 2020 |
Renal asymmetric dimethylarginine inhibits fibrosis.
Topics: Amidohydrolases; Animals; Arginine; Disease Models, Animal; Fibronectins; Fibrosis; Kidney; Kidney D | 2020 |
Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia.
Topics: Aged; Amidohydrolases; Anemia; Animals; Arginine; Cytokines; Drug Resistance; Erythrocyte Indices; E | 2017 |
Renalase Assessment With Regard to Kidney Function, Lipid Disturbances, and Endothelial Dysfunction Parameters in Stable Renal Transplant Recipients.
Topics: Adult; Antihypertensive Agents; Arginine; C-Reactive Protein; Case-Control Studies; Cholesterol; Cho | 2017 |
Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arginine; beta 2-Microglobulin; Creatinine; Female; H | 2017 |
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Chromatography, Liquid; Disease Progression; Fe | 2018 |
Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function.
Topics: Animals; Arginine; Disease Models, Animal; Glutathione Peroxidase; Heart Diseases; Mice; Mice, Knock | 2018 |
Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Case-Control Studies; Diabetes Complications; Diabetes Mell | 2018 |
Endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease.
Topics: Arginine; Atherosclerosis; Endothelium; Humans; Radial Artery; Renal Insufficiency, Chronic | 2018 |
Asymmetric dimethylarginine as a useful risk marker of radial artery calcification in patients with advanced kidney disease.
Topics: Aged; Arginine; Biomarkers; Calcinosis; Female; Humans; Male; Middle Aged; Radial Artery; Renal Insu | 2018 |
Gender differences in the relationships between chronic kidney disease, asymmetric dimethylarginine, and sleep quality: The HEIJO-KYO cohort.
Topics: Aged; Arginine; Cohort Studies; Female; Humans; Male; Multivariate Analysis; Quality of Life; Renal | 2018 |
FGF23 impairs peripheral microvascular function in renal failure.
Topics: Animals; Arginine; Cells, Cultured; Coronary Circulation; Coronary Vessels; Disease Models, Animal; | 2018 |
LC-QQQ-MS routine analysis method for new biomarker quantification in plasma aimed at early chronic kidney disease diagnosis.
Topics: Arginine; Biomarkers; Child; Child, Preschool; Chromatography, Liquid; Citrulline; Creatinine; Early | 2019 |
Distinct associations between plasma osteoprotegerin, homoarginine and asymmetric dimethylarginine in chronic kidney disease male patients with coronary artery disease.
Topics: Aged; Arginine; Biomarkers; Coronary Artery Disease; Homoarginine; Humans; Male; Middle Aged; Osteop | 2019 |
Establishment of reference values for the lysine acetylation marker N
Topics: Adolescent; Adult; Arginine; Biomarkers; Cardiovascular Diseases; Carnitine; Chromatography, Liquid; | 2019 |
Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.
Topics: Adult; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies | 2013 |
Endothelial cell transfusion ameliorates endothelial dysfunction in 5/6 nephrectomized rats.
Topics: Acetylcholine; Amidohydrolases; Animals; Aorta; Arginine; Disease Models, Animal; Endothelial Cells; | 2013 |
Soluble TWEAK plasma levels increase after renal transplantation and associate with the improvement of endothelial function.
Topics: Adult; Arginine; Biomarkers; Brachial Artery; C-Reactive Protein; Cytokine TWEAK; Endothelium, Vascu | 2013 |
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.
Topics: Adult; Aged; Alleles; Amidohydrolases; Arginine; Female; Glomerular Filtration Rate; Humans; Male; M | 2013 |
Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass.
Topics: Amidohydrolases; Animals; Aorta; Apolipoproteins E; Arginine; Atherosclerosis; Disease Models, Anima | 2014 |
Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
Topics: Advanced Oxidation Protein Products; Aged; Arginine; Biomarkers; Case-Control Studies; Disease Progr | 2014 |
Serum reference intervals of homoarginine, ADMA, and SDMA in the study of health in Pomerania.
Topics: Adult; Aged; Arginine; Biomarkers; Body Mass Index; Cardiovascular Diseases; Chromatography, High Pr | 2014 |
Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.
Topics: Adult; Aged; Arginine; Biomarkers; Case-Control Studies; Chromatography, High Pressure Liquid; Femal | 2014 |
Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD.
Topics: Adult; Aged; Arginine; Cohort Studies; Disease Progression; Female; Fibroblast Growth Factor-23; Fib | 2015 |
Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Topics: Aged; Alleles; Arginine; C-Reactive Protein; Calcium; Case-Control Studies; Cohort Studies; Creatini | 2015 |
Association of advanced age with concentrations of uraemic toxins in CKD.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Arginine; beta 2-Microglobulin; Biomarkers; Bloo | 2016 |
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease.
Topics: Adult; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Fe | 2015 |
Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease.
Topics: Animals; Arginine; Brain-Derived Neurotrophic Factor; Cohort Studies; Cross-Sectional Studies; Depre | 2015 |
The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats.
Topics: Adipose Tissue; Amidohydrolases; Animals; Arginine; Blotting, Western; Cells, Cultured; Gene Express | 2016 |
Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiffness in childhood chronic kidney disease.
Topics: Adolescent; Arginine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Citr | 2016 |
Effect of inflammation by acute sepsis on intact fibroblast growth factor 23 (iFGF23) and asymmetric dimethyl arginine (ADMA) in CKD patients.
Topics: Arginine; Biomarkers; Case-Control Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth F | 2016 |
Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
Topics: Aged; Arginine; Biomarkers; Case-Control Studies; Echocardiography, Doppler; Endothelium, Vascular; | 2016 |
Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA.
Topics: Arginine; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; Humans; Renal Ins | 2016 |
Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease.
Topics: Adult; Arginine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Male; Middle A | 2016 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema | 2016 |
Risk factors for chronic kidney disease do not influence the serum levels of asymmetric dimethylarginine in HIV-1-infected patients without significant renal disease.
Topics: Adult; Aged; Anti-HIV Agents; Arginine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Re | 2016 |
Asymmetric dimethylarginine: a risk indicator or pathogenic factor?
Topics: Arginine; HIV Infections; HIV-1; Humans; Renal Insufficiency, Chronic | 2016 |
Relation between asymmetric dimethylarginine (ADMA) and hearing loss in patients with renal impairment.
Topics: Adult; Arginine; C-Reactive Protein; Case-Control Studies; Creatinine; Female; Hearing Loss, Sensori | 2008 |
Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.
Topics: Adult; Arginine; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Male; M | 2009 |
HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
Topics: Adolescent; Adult; Aged; Arginine; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Cr | 2010 |
Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease.
Topics: Adult; Arginine; Female; Follow-Up Studies; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Esti | 2010 |
Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.
Topics: Animals; Arginine; Collagen; Endothelin-1; Enzyme Inhibitors; Fibrosis; Gene Expression Regulation; | 2011 |
Ascorbic acid or L-arginine improves cutaneous microvascular function in chronic kidney disease.
Topics: Adult; Arginine; Ascorbic Acid; Case-Control Studies; Female; Hot Temperature; Humans; Male; Microci | 2011 |
Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
Topics: Amidohydrolases; Animals; Arginine; Disease Models, Animal; Endothelium, Vascular; Human Umbilical V | 2012 |
ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine.
Topics: Animals; Arginine; Humans; Male; Nitric Oxide Synthase Type III; Renal Insufficiency, Chronic | 2012 |
Diagnostic value of plasma asymmetric and symmetric dimethylarginine levels in liver transplant recipients.
Topics: Alanine Transaminase; Arginine; Aspartate Aminotransferases; Biomarkers; Cadaver; Fibrosis; Humans; | 2012 |
Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
Topics: Aged; Amidohydrolases; Arginine; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Ty | 2013 |